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The  evasion  of  anti-growth  signaling  is an  important  characteristic  of cancer  cells.  In order  to con-
tinue  to  proliferate,  cancer  cells  must  somehow  uncouple  themselves  from  the  many  signals  that
exist  to slow  down  cell  growth.  Here,  we  deﬁne  the  anti-growth  signaling  process,  and  review  sev-
eral  important  pathways  involved  in growth  signaling:  p53,  phosphatase  and  tensin  homolog  (PTEN),
retinoblastoma  protein  (Rb),  Hippo,  growth  differentiation  factor  15  (GDF15),  AT-rich  interactive  domain
1A (ARID1A),  Notch,  insulin-like  growth  factor  (IGF),  and  Krüppel-like  factor  5  (KLF5)  pathways.  Aber-
rations  in  these  processes  in  cancer  cells  involve  mutations  and  thus  the  suppression  of  genes  that
prevent  growth,  as  well  as  mutation  and activation  of genes  involved  in  driving  cell  growth.  Usingallmark of cancer
these  pathways  as examples,  we  prioritize  molecular  targets  that  might  be  leveraged  to promote  anti-
growth  signaling  in cancer  cells.  Interestingly,  naturally  occurring  phytochemicals  found  in human  diets
(either  singly  or  as  mixtures)  may  promote  anti-growth  signaling,  and  do so  without  the  potentially
adverse  effects associated  with  synthetic  chemicals.  We  review  examples  of  naturally  occurring  phyto-
chemicals  that  may  be  applied  to  prevent  cancer  by antagonizing  growth  signaling,  and  propose  one
phytochemical  for  each  pathway.  These  are: epigallocatechin-3-gallate  (EGCG)  for the  Rb  pathway,
∗ Corresponding author at: Winship Cancer Institute of Emory University, 1365-C Clifton Road, Atlanta, GA, 30322, USA. Tel.: +1 404 778 5990; fax: +1 404 778 5520.
E-mail  address: dmshin@emory.edu (D.M. Shin).
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luteolin  for  p53,  curcumin  for  PTEN,  porphyrins  for Hippo,  genistein  for GDF15,  resveratrol  for  ARID1A,
withaferin  A  for Notch  and  diguelin  for the IGF1-receptor  pathway.  The  coordination  of  anti-growth
signaling  and  natural  compound  studies  will  provide  insight  into  the  future  application  of these  com-
pounds  in  the  clinical  setting.
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. Introduction
Carcinogenesis is a complex, stochastic and yet highly coordi-
ated multi-step process in which normal cells progress through
yperplasia to mild, moderate and severe dysplasia to carcinoma
n situ, invasive carcinoma, and ﬁnally to metastatic disease after
nitiation by primary carcinogenic insult [1]. Hahn and Wein-
erg [2] proposed six hallmarks to better deﬁne and understand
his complex process. They modeled these hallmarks in normal
uman bronchial epithelial cells and demonstrated immortaliza-
ion in vitro by targeting tumor suppressor pathways, notably,
etinoblastoma (Rb) regulation of cell cycle entry, tumor protein
3 (TP53) regulation of cell cycle progression, human telomerase
everse transcriptase (hTERT) activation, combined with an onco-
enic signal using activated Harvey rat sarcoma viral oncogene
omolog (hRAS) [3]. As this model shows, and as studies of human
umors progress into the era of high throughput sequencing, it is
lear that evasion of anti-growth signaling and loss of tumor sup-
ressors are central hallmarks necessary to the oncogenic process.
Loss of growth control mechanisms allows neoplastic cells to
cquire unlimited replicative ability and evade elimination, growth
rrest, and senescence by tumor suppressors. In general, tumor sup-
ressor genes block the transformation of normal cells to cancerous
ells. Environmental stress factors including ultraviolet (UV), irra-
iation, and chemicals can induce DNA damage and genetic
lteration. These injuries can cause the progression of carcinogenic
rocesses if damage cannot be appropriately repaired and mutated
ells continuously proliferate. Dozens of tumor suppressor genes
re activated under these circumstances that inhibit the prolifera-
ion of damaged/mutated cells by arresting cell cycle progression
nd inducing apoptosis and other types of programmed cell death,
hus their evasion is critical for carcinogenesis. p53 and Rb are
ypical tumor suppressor genes [4]; they play a key role in deter-
ining the fate of cells, i.e. whether they proliferate or undergo
enescence or apoptotic programs. In solid tumors, the most com-
on genetic changes are losses of tumor suppressor genes. It has
een estimated that over 70% of the genetic changes discovered in
olid tumors represent evasion of tumor suppressor mechanisms;
eading to the suggestion that this leaves us with an un-targetable
ancer problem. It would appear necessary to replenish the func-
ion associated with the mutated or lost tumor suppressor in every
umor cell, a goal that has so far been unattainable. However, loss
f a tumor suppressor usually results in unopposed signaling by
 mechanism normally suppressed by the lost tumor suppressor
ene. Thus, a viable strategy to overcome the evasion of a tumor
uppressor mechanism is to identify and target the unrestrained
athways activated by the loss of tumor suppressors.
This review will brieﬂy discuss how anti-growth signaling
echanisms are inactivated in tumors with emphasis on major
umor suppressor pathways and will explore how these pathways
an be targeted for the prevention and treatment of cancer.
. Dysfunction: mechanism of evasion of tumor
uppressors
Tumor cells may  evade tumor suppressors by genetic and epi-
enetic mechanisms. Genetic mechanisms include chromosomal Ltd.  This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
deletion, mutation and inactivation or loss of upstream or down-
stream effectors. Epigenetic evasion includes DNA methylation, and
histone methylation and acetylation. Examples of tumor suppres-
sor losses are abundant in solid tumors. Among the most common
are loss, mutation and/or methylation of the cyclin-dependent
kinase inhibitor (CDKN) 2A locus on chromosome 9p21, which leads
to loss of the CDKN, p16ink4a and often the mouse double minute
2 homolog (hMDM2) inhibitor p14ARF as well. Loss of p16ink4a
results in unopposed activation of the cyclin dependent kinases
CDK4/6, which phosphorylate the Rb protein thereby activating
E2F-mediated transcription of genes involved in entry into the cell
cycle. Loss of p14ARF protein results in unopposed MDM2  activ-
ity and increased p53 ubiquitination and degradation with effects
similar to loss of p53. Mutation, loss or inhibition of TP53 function
is also very common, as is loss and/or mutation of phosphatase
and tensin homolog (PTEN). Loss of p53 leads to loss of cell cycle
checkpoints, the ability of the cell to arrest and effectively repair
DNA errors or damage and the accumulation of genetic instabil-
ity and accumulation of mutations. Additionally, p53 protein has
an important role in triggering apoptosis, thus its loss leads to the
inappropriate survival of cells with new mutations. Loss of PTEN
protein, a phosphatase that dephosphorylates phosphatidylinositol
(3,4,5)-trisphosphate (PIP3), leads to unopposed activity of phos-
phoinositide 3-kinase (PI3K) and protein kinase B (AKT) signaling,
which drives tumor growth.
The dysfunctional pathways activated by loss of tumor sup-
pressors provide continuous unopposed tumor growth promoting
signals. These pathways have consequently become potential tar-
gets for novel anti-cancer compounds. For example, inhibitors of
MDM2  are being tested to restore p53 function, mammalian target
of rapamycin (mTOR) inhibitors are being tested to overcome PTEN
loss, and CDK4/6 inhibitors to restore Rb function from p16ink4a
loss of function are entering clinical trials.
3. Prioritized anti-growth signaling pathways
There are hundreds of tumor suppressor genes that possess the
ability to stop or slow down the carcinogenesis process. The activa-
tion of tumor suppressors is mostly context-dependent and varies
by organ site and by molecular and pathological sub-type. The most
common and important tumor suppressors, their role in tumori-
genesis and approaches to target these genes for cancer treatment
and prophylaxis are discussed in the following sections and sum-
marized in Fig. 1.
3.1. The Rb pathway
The retinoblastoma (Rb) gene was the ﬁrst tumor suppressor
gene to be described. The development of retinoblastoma was pre-
dicted by Alfred Knudsen to involve a “two hit” mechanism, based
on the kinetics of appearance of retinoblastoma in the inherited
form (single order kinetics) and the sporadic form (second order
kinetics). This analysis led to the hypothesis that disease initiation
requires two steps involving loss of function of both copies of the
affected gene. Thus, Rb was recognized to have a tumor suppressor
function long before the gene was  identiﬁed and demonstrated to
be inactivated by mutation of one copy and loss or silencing of the
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econd copy [5]. The Rb protein (pRb) also plays a key role in inte-
rating diverse signals from intra- and extracellular sources and
hus driving cell cycle progression. In cells in the G0/G1 phase, pRb,
hich is in a hypophosphorylated state, binds to the transcription
actor E2F family and suppresses E2F-mediated gene transcription.
he E2F family encodes a variety of genes involved in cell cycle
rogression, DNA replication, DNA damage repair, cell cycle check-
oint, and apoptosis [6]. Therefore, inhibition of the E2F family by
Rb results in the suppression of cell cycle progression. However,
he cyclin D/CDK4 complex phosphorylates pRB and allows E2Fs to
ind their target genes by disrupting the formation of the pRB–E2F
omplex [7]. In addition to controlling cell cycle progression, pRB is
lso involved in the regulation of DNA replication, differentiation,
nd apoptosis [7].
In head and neck squamous cell cancers (HNSCC), loss or muta-
ion of Rb is uncommon [1], but frequent inactivation by loss,
utation and/or methylation of p16 (CDKN2/MTS-1/INK4A) was
bserved in the majority of tumors [8]. In fact, p16ink4a was ﬁrst
alled the multiple tumor suppressor gene-1 (MTS-1) because it is
o commonly inactivated in many tumor types (melanoma, breast,
ead and neck, etc.). Abnormalities in CDKN2A RB1 are found in
reater than 70% of lung squamous cancers [9], consistent with the
bservations in HNSCC. The p16 protein regulates Rb by acting as
n inhibitor of the cyclin dependent kinases that phosphorylate
b, thereby allowing the E2F family of transcription factors to ini-
iate expression of genes involved in entry into the cell cycle. In an
mportant feedback loop, E2F upregulates p16ink4a protein expres-
ion, which inactivates the cyclinD1/CDK4/6 complex (Fig. 2). With
DK4/6 inactivated, Rb is de-phosphorylated by ubiquitous phos-
hatases and re-sequesters E2F, preventing cell cycle entry.
.2. The p53 pathway
The tumor suppressor p53 family consists of three members,
53, p63 and p73, sharing overlapping anti-growth functions, such
s cell cycle arrest, apoptosis and DNA repair. TP53 is very fre-
uently targeted by mutation and loss in cancer. In the recent report
f The Cancer Genome Atlas (TCGA) assessment of squamous cell
ung cancers, the most common signiﬁcantly mutated gene was
P53 [9]. Mutation and loss of p53 are very common in cancers
elated to carcinogens in tobacco smoke, such as lung, head andways and their targeting by natural compounds.
neck, bladder, etc., but are less common in breast and prostate can-
cers that have hormonal, genetic and diet-related etiologic factors.
In a subset of cancers that retain wild type p53, loss of p14ARF can
result in unopposed activity of MDM2,  which is a transcriptional
target and a negative regulator of p53. MDM2  is a p53-speciﬁc
E3 ubiquitin ligase that physically interacts with p53, causing its
mono-ubiquitination and thus its degradation [10]. Disruption of
the p53-MDM2 interaction leads to p53 induction and its biological
response such as cell cycle arrest, DNA damage repair and apopto-
sis. In this subset, MDM2  inhibitors are effective at restoring p53
function leading to growth inhibition and induction of apoptosis
[11].
In cancers caused by oncogenic viruses, such as the high risk
human papilloma viruses (hrHPV), which are implicated in anogen-
ital and oropharyngeal cancers, p53 and p16ink4a are nearly always
wild type. Currently, 70–90% of oropharyngeal cancers diagnosed at
the University of Michigan contain hrHPV [12]. The viral oncogenes
E6 and E7 target and inactivate p53 and Rb, respectively. E7 binds
to Rb protein preventing it from binding to E2F, which then acti-
vates continuous transcription of genes involved in cell cycle entry
and of p16 (Fig. 3). For this reason, overexpression of p16 is a useful
surrogate for hrHPV infection. These tumors are also more respon-
sive to therapy, most likely because the p53 and Rb genes are intact,
and after treatment can still function if the virus is inactivated by
chemotherapy and radiation. However, some HPV-positive tumors
are also controlled by surgery [13], suggesting that an immune
response to the virus may  assist in eliminating the tumor.
Mutation and loss of p53 function can be an Achilles heel for
cytotoxic therapies such as cisplatin. Cisplatin binds to DNA to
cause its cytotoxic effect. When p53 is compromised by mutation it
is less effective in causing cell cycle arrest and DNA repair. Thus, the
degree of lethal damage to tumor cells caused by cisplatin is often
increased when p53 is mutated or inactivated because the cell can-
not undergo p53-mediated cell cycle arrest and p53-mediated DNA
repair.
DNA damage or stress response mediated by chemicals, UV
irradiation, or oncogenic mutation results in the stabilization and
accumulation of p53 [14,15]. Activated p53 can bind to speciﬁc DNA
sequences in the promoter region of its target genes, including p21,
B-cell lymphoma 2 (Bcl2)-associated X protein (Bax), p53 upregulated
modulator of apoptosis (PUMA), and growth arrest and DNA damage
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Fig. 2. Cyclin D1 and p16 regulate cell cycle entry. Whe
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GADD45),  mediating cell cycle arrest, senescence, and apoptosis
16]. In contrast to these suppressive roles, mutant p53 loses these
unctions and serves as an oncogene by physically interacting with
ther proteins and thus modulating their cellular function [17]. For
xample, the interaction between mutant p53 and p63 results in the
ecreased tumor suppressive activity of p63 [17]. A recent report
uggests that the interaction of mutant p53 with Smad negatively
egulates p63, leading to cancer cell metastasis [18]. Mutant p53
s also known to associate with several transcription factors, such
s speciﬁcity protein 1 (Sp1), Ets-1, and vitamin D receptor (VDR),
esulting in the transactivation of their oncogenic target genes [17].
Although p53 is inactivated through deletion or mutation in
bout half of all cancers, mutation of p63 and p73 are extremely rare
n human cancers [19–23], although their expression is frequently
ysregulated in human tumors [19]. p73 mRNA and/or protein were
hown to be upregulated in breast [24,25], ovarian [26], hepatocel-
ular [27], neuroblastoma [28], bladder [29], prostate [30], thyroid
31], B-cell chronic leukemias [32] and colorectal [33] cancers, andn p16 is lost, CDK inhibitors can restore function.
lost in pancreatic adenocarcinoma [34]. Expression of Np73 iso-
forms was  also increased in head and neck cancers [35]. These
members of the p53 family are also targets of many anti-cancer
drugs including those frequently used in the clinic such as cisplatin.
3.3. The phosphatase and tensin homolog (PTEN) pathway
PTEN is often lost or inactivated in multiple solid tumor types
including prostate, breast, thyroid, and endometrial tumors and
others [36]. PTEN is a critical regulator of signaling through the
PI3K pathway through its action as a PIP3 phosphatase, thereby
negatively regulating the PI3K-AKT-mTOR pathway. In the absence
of PTEN, unregulated cell proliferation occurs through activation of
a cascade of signals downstream in the AKT pathway. Fortunately,
mTOR inhibitors [37] and mitogen/extracellular signal-regulated
kinase (MEK) inhibitors [38] are being developed that can tar-
get these pathways, providing a strategy to counter this common
tumor suppressor loss. For instance, mTOR inhibitors such as
everolimus and temsirolimus targeting the PI3/AKT pathway,
which is overexpressed as a consequence of PTEN loss, have been
shown to improve median overall survival in renal cell carcinomas
and pancreatic neuroendocrine carcinomas.
Loss or inactivation of PTEN also inactivates the forkhead box
“O” (FOXO) family of tumor suppressors through AKT. The family
consists of four members, FOXO1 (also known as FKHR), FOXO3a
(also known as FKHRL1), FOXO4 (also known as AFX or MLLT7),
and FOXO6. FOXO proteins are well characterized tumor suppres-
sors: simultaneous somatic deletions of FOXO1, 3 and 4 alleles
generates thymic lymphomas and systemic hemagiomas in mice
(reviewed in [39]). FOXOs are direct substrates of AKT and AKT-
dependent phosphorylation sequesters them in the cytoplasm and
promotes their degradation through ubiquitylation, thus inactivat-
ing them. FOXOs can undergo multiple other post-translational
modiﬁcations (PTMs) [39], which affect their transcriptional activ-
ity and contribute to tumor initiation, progression and drug action.
FOXO proteins transcribe genes involved in G0/G1 cell cycle transi-Polo-like kinase 1) and apoptosis (BIM, BCL6, PUMA,  TNF-related
apoptosis-inducing ligand [TRAIL], etc.). Since FOXOs are mostly
inactivated through activation of PI3K-AKT pathways, these tumor
A.R.M.R. Amin et al. / Seminars in Can
F
p
s
w
t
i
3
o
c
u
o
r
c
(
a
s
t
(
(
m
w
T
c
t
t
l
p
c
b
r
a
lig. 4. Hippo signaling inhibits YAP/TAZ-mediated activation of genes involved in
roliferation and survival.
uppressors can be easily activated by targeting PI3K-AKT path-
ays. Multiple small molecule inhibitors have been developed that
arget PI3K or AKT and many of them are currently under clinical
nvestigation.
.4. The Hippo pathway
The Hippo signaling pathway has emerged as a central regulator
f growth, connecting processes such as adhesion, cell polarity, and
ell density with increases in cell number [40–42]. Overcoming the
pstream regulators of the Hippo pathway may  be a prerequisite,
r hallmark feature, of certain cancer cell types [43].
The core Hippo pathway is highly conserved, and functions to
estrict growth during development by limiting the output of pre-
ursor cells [42]. In this pathway, the Ste20-like kinase MST1/2
Hippo) works with the adaptor Salvador (SAV) to phosphorylate
nd activate the nuclear Dbf2-related (NDR)-like kinase large tumor
uppressor kinase (LATS1/2). In turn, LATS activity with the adap-
or, MOB, results in the phosphorylation of Yes-associated protein
YAP) and transcriptional coactivator with PDZ-binding motif (TAZ)
Fig. 4) [41,42]. This phosphorylation of YAP leads to its accu-
ulation in the cytoplasm where it has been shown to associate
ith 14-3-3, angiomotin (AMOT), or catenin 1 (CTNNA1) [44,45].
he phosphorylation and exclusion of YAP from the nucleus is
ritical because it prevents its activity as a transcriptional coac-
ivator. If it enters the nucleus, YAP increases cell production, both
hrough proliferation and the inhibition of cell death. Hence, the
oss of core components such as MST  or LATS prevents YAP/TAZ
hosphorylation and activates YAP targets. The cytoplasmic asso-
iation of YAP/TAZ with AMOT and CTNNA1 is also signiﬁcant,
ecause when these cytoskeletal or cell adhesion scaffolds are dis-
upted, the cytosolic pool of YAP/TAZ changes. Thus, disruption of
dhesion, cytoskeletal, and cell polarity proteins can drive cell pro-
iferation through YAP. There are numerous additional regulators ofcer Biology 35 (2015) S55–S77 S59
core pathway members, including: cadherin 1 (CDH1), CD44, FERM
domain containing 6 (FRMD6), protein associated with Lin Seven 1
(PALS1), PATJ, AJUBA, Ras-associated family members (RASSF), and
G-protein coupled receptors (GPCRs) [40,41]. The relative contrib-
utions of these multiple inputs to the core members is not resolved,
although it is likely that several such inputs may exist at any one
time in the same cell.
Loss of core Hippo pathway components, or hyperactivation of
YAP/TAZ, in adult mouse precursor cells has been shown to result in
hyperplasia and tumorigenesis [40,42]. Overall, this suggests that
Hippo pathway disruption promotes cancer [40]. Consistent with
this notion, YAP has been observed to undergo copy number ampli-
ﬁcation in both human cancer and mouse cancer models [46,47].
The Hippo pathway regulator neuroﬁbromatosis 2 (NF2) provides
another example of how cancer may  result through YAP activation.
NF2 is listed in the Catalogue of Somatic Mutations in Cancer (COS-
MIC) gene database and NF2 loss of function results in the formation
of schwanommas [40,48–50]. Functional assays have shown that
NF2 regulates YAP activity, and YAP is required for the overgrowth
observed when NF2 is lost in vivo [51].
Genomic analyses by TCGA or COSMIC do not show an enrich-
ment of core Hippo pathway members in cancer [40]. It is unclear
why this is the case. Perhaps unidentiﬁed components, which link
cell adhesion or cytoskeletal proteins with the Hippo pathway, are
lost in cancers rather than the core members. Alternatively, epige-
netic factors that regulate the expression of core Hippo components
could be disrupted in cancer. Regulation of the Hippo pathway by
other signaling processes is another means through which cancer
cells overcome the growth restrictions normally imposed on tissue
cells by the Hippo pathway [40]. For instance, the Wnt  signaling
pathway component disheveled segment polarity protein 1 (DVL1)
binds to phosphorylated YAP/TAZ, inhibiting Wnt  signaling [52,53].
Thus, loss of Hippo activity could de-phosphorylate YAP and simul-
taneously activate the Wnt  pathway. Hyperactive Wnt  itself is
thought to drive colorectal cancer through the activation of its
target, catenin 1 (CTNNB1) [54], and YAP can bind and syner-
gize with CTNNB1 in some contexts [55]. The disruption of Hippo
signaling could be quite signiﬁcant in cancer by enabling prolifer-
ation through multiple other pathways.
YAP/TAZ function as transcriptional coactivators of transcrip-
tion factors such as p73, TEA domain family member 1 (TEAD),
SMAD, and possibly others [40,42]. YAP/TAZ nuclear activity
increases the transcription of many genes including baculoviral IAP
repeat-containing proteins (BIRC) 2 and 5, marker of proliferation
Ki67, connective tissue growth factor (CTGF), and amphiregulin
[56–58]. Such targets reveal how YAP activity leads to increased cell
production: Ki67 leads to greater proliferation, CTGF and amphireg-
ulin inﬂuence further signaling processes, and BIRC2/5 inhibit
apoptosis. Moreover, Hippo and Wnt, or transforming growth
factor (TGF)- signaling are integrated [41], and some work on
intestinal precursors reveals that the Janus kinase 2 (JAK)/signal
transducer and activator of transcription (STAT) and epidermal
growth factor (EGF) pathways may also be activated through YAP
[59,60]. The effects of Hippo signaling disruption could therefore
inﬂuence the output of multiple signaling pathways that regulate
the hallmarks of cancer [43].
Since the Hippo pathway suppresses cell growth by inhibiting
YAP/TAZ, the desired intervention is to either enhance Hippo sig-
nal transduction or to inhibit YAP/TAZ activity. Drugs inhibiting
the core kinases are not useful, but it may  be possible to develop
drugs targeting the phosphorylation sites on YAP/TAZ, which are
known [41,42], or drugs that prevent the activity of YAP/TAZ. For
instance, small molecule screening has revealed three porphyrins
that prevent the association of YAP with TEAD transcription fac-
tors [61]. One of these, verteporﬁn, is already applied clinically to
treat macular degeneration. It is therefore possible that porphyrins
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ould be applied in treating cancers where NF2 function has been
ost without impacting normal tissue function.
A recent report has shown that GPCR signaling can both stim-
late and repress the core Hippo kinases [62]. The GPCR agonists,
ysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P),
an inhibit the core Hippo pathway member, LATS, which directly
hosphorylates and inhibits YAP/TAZ. However, GPCR activation
an also produce the opposite outcome. Adrenergic receptors,
or instance stimulated by epinephrine, can actually increase the
hosphorylation of YAP/TAZ by LATS, meaning that Hippo signal
ransduction can be enhanced [62]. GPCR signaling is complex in
hat the involved ligands, GPCRs, and G- proteins work in a com-
inatorial and tissue-speciﬁc fashion. This speciﬁcity presents an
pportunity to develop context-speciﬁc interventions that inhibit
roliferation by agonizing the activity of LATS.
The Hippo pathway is just one of many mechanisms that sup-
ress growth, but its disruption has extremely potent effects on cell
roliferation. Future treatments of cancers that evade Hippo path-
ay growth suppression are likely to involve inhibition of YAP or
nhancement of the upstream Hippo components that negatively
egulate it.
.5. Growth differentiation factor 15 (GDF15)
GDF15, also known as nonsteroidal anti-inﬂammatory drug
NSAID)-activated gene-1 (NAG-1), macrophage inhibitory
ytokine 1 (MIC-1), placental TGF- (PTGF-), prostate differen-
iation factor (PDF), and placental bone morphogenetic protein
PLAB), is structurally similar to TGF- [63]. TGF- has established
oles as both a growth suppressor and growth stimulator in
ancer cells. Similarly, GDF15 exhibits growth suppressive and
rowth-promoting effects, which may  depend in part on the stage
f disease [64,65]. In comparison to other cytokines and tran-
cription factors, GDF15 has not been extensively studied in the
ontext of cancer cell growth suppression. However, accumulating
ata suggest that GDF15 has multiple functions in cancer cells,
ncluding roles in the evasion of anti-growth signaling.
The growth-suppressing function of GDF15 may  be due in part to
he presence of p53 response elements within its promoter. GDF15
s a p53 transcriptional target that mediates G1 cell cycle arrest
nd apoptosis [66,67]. In addition to its p53-dependent activity,
DF15 has been shown to reduce cancer cell growth through other
echanisms. The Krüppel-like factor 4 (KLF4) tumor suppressor
lso binds to the GDF15 promoter and initiates transcription of
DF15 in pancreatic cancer cells [68]. Other transcriptional medi-
tors of GDF15 identiﬁed in colorectal cancer cell lines include
p1, Sp3, and early growth response 1 (EGR1) [69,70]. Finally,
eroxisome proliferator-activated receptor gamma  (PPAR)  ligand
as been shown to induce GDF15 expression in pancreatic and
olon cancers [68,71,72]. Thus, there are several major transcrip-
ional regulators of growth suppression that upregulate GDF15.
owever, similar to TGF-, GDF15 also exhibits growth-promoting
ffects. In fact, serum levels of GDF15 are frequently elevated
n patients with various types of cancer, including pancreatic,
rostate, and ovarian cancers. Therefore, although GDF15 appears
o play a role in regulating the growth of cancer cells, its exact
unctions and mechanisms of action remain incompletely deﬁned
nd may  vary depending on cellular and disease context. In addi-
ion, GDF15 is upregulated by various signaling molecules, such as
itogen-activated protein kinase (MAPK) family members. Various
hemical compounds, including 12-O-tetradecanoylphorbol-13-
cetate (TPA), vitamin E, NSAID agents, and the proteasome
nhibitor MG132 induce the transcription of GDF15/NAG-1 in a p38
APK-dependent manner [73–76]. Interestingly, MG132 increased
DF15 at the promoter level and stabilized the GDF15 transcript. In
ddition to being regulated by MAPK signaling, GDF15 expressioncer Biology 35 (2015) S55–S77
is regulated by PI3K/Akt/glycogen synthase kinase-3 beta (GSK-
3) signaling [77], with PI3K inhibition inducing GDF15/NAG-1
expression. However, pharmacological inhibition or genetic knock-
down of GSK-3,  which is negatively regulated by PI3K/Akt, blocks
the upregulation of GDF15/NAG-1 in response to PI3K inhibition.
Thus, PI3K signaling may  suppress GDF15 expression in some con-
texts, whereas PI3K/Akt inhibitors induce GDF15 via GSK-3.  This
induction of GDF15 may  contribute to the growth suppressive or
apoptotic effects of pharmacological PI3K inhibitors. Conversely,
PI3K/MAPK signaling pathways are also implicated in the growth-
promoting effects of GDF15. Stimulation or overexpression of
GDF15 induces phosphorylation of Akt, p38 MAPK, and extracellu-
lar signal-regulated kinases (ERK1/2) in breast and ovarian cancer
cells [78,79]. These seemingly paradoxical results suggest context-
dependent effects and possible feedback pathways that regulate
GDF15 expression and/or activity.
GDF15 has potential roles in growth suppression as well as in
metastasis and invasion. Increased circulating levels of secreted
GDF15 or increased tissue expression are reported in patients with
colorectal [80], ovarian [78,81,82], prostate [83–85], pancreatic
[86,87], breast [88], and bladder [89] cancers and in the cere-
brospinal ﬂuid of patients with glioblastoma [90], suggesting that
GDF15 may  serve as a cancer biomarker and potential therapeu-
tic target in advanced cancers. However, targeting GDF15 must
be carefully considered, given its possible role in the growth sup-
pression of early-stage cancers. Increased metastasis, invasiveness,
proliferation, and migration have been observed in the presence
of GDF15 overexpression. However, the signaling pathways con-
tributing to these biological events appear to vary between cancer
types and remain largely uncharacterized.
GDF15 stimulates proliferation via ERK activation in prostate
cancer cell lines [91–93]. GDF15 stimulation has been shown to
activate phosphorylation of the receptor tyrosine kinase human
epidermal growth factor receptor 2 (erbB2/HER2) [79,94]. Src inhi-
bition partially disrupts this phosphorylation [79], suggesting that
GDF15 may  mediate crosstalk to HER2 from another unidenti-
ﬁed receptor. GDF15 stimulation results in reduced response to
the HER2 monoclonal antibody, trastuzumab [79], and knock-
down of GDF15 improves response to trastuzumab [79]. MAPK and
PI3K/mTOR signaling pathways are activated by GDF15 [78,79]; for
example, mTOR inhibition by rapamycin overcomes the increased
invasive phenotype of GDF15-stably transfected ovarian cancer
cells [78]. Further, this GDF15-mediated invasion is matrix met-
alloproteinase (MMP)-dependent [78]. Increases in gelatinolytic
activity and upregulation of the urokinase plasminogen activa-
tor (uPA) system are also linked to GDF15-mediated invasiveness
in gastric cancer cell lines but in an ERK1/2-dependent manner
[95]. The role of TGF- receptor in this process and the exact
signaling mechanisms that mediate resistance and invasion in
GDF15-overexpressing breast or ovarian cancer cells remain to be
established.
GDF15 serum levels are increased in colon cancer patients
treated with non-steroidal anti-inﬂammatory drugs in association
with reduced tumor recurrence [80]. Non-synonymous protein-
coding single nucleotide polymorphisms (nsSNPs) that cause a
cytosine-to-guanine (C-to-G) substitution at exon 202 of the GDF15
precursor protein have been identiﬁed in patients with prostate
cancer. This substitution, known as H6D, is associated with a
reduced risk of developing prostate cancer [96–98]. However, one
study showed that prostate cancer patients with this CG muta-
tion suffered a higher mortality rate versus the CC genotype [97].
Thus, the exact functional changes induced by the mutation and the
validity of this genetic change as a predictor of survival or cancer
biomarker remain to be determined.
The strongest evidence that GDF15 suppresses tumor
growth has been obtained in mouse models in which GDF15
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verexpression decreased tumorigenesis in models of lung cancer
99], breast cancer [100], prostate cancer [101], glioblastoma
102], and colon carcinoma [103]. Further, GDF15 transgenic
ice developed fewer carcinogen-induced lung [99] or colorectal
103] tumors relative to control mice. Cross-breeding of GDF15
ransgenic and transgenic adenocarcinoma of the mouse prostate
TRAMP) mice resulted in signiﬁcantly fewer tumors, which
ere lower in grade compared to those in the control TRAMP
ice. However, tumors in GDF15/TRAMP mice showed increased
etastasis [93]. These results are particularly intriguing given
he paradoxical results that have been reported for GDF15 in the
iterature. The data suggest that GDF15 may  function as a growth
uppressor in pre-malignant or early stages of cancer, but that a
ro-growth/pro-invasive phenotype is stimulated by GDF15 in
dvanced tumors.
GDF15 also has putative anti-inﬂammatory activities. GDF15
ppears to suppress secretion of inﬂammatory cytokines from
ipopolysaccharide-treated macrophages [63]. Indeed, GDF15
ransgenic mice exposed to a carcinogen show reduced lung tissue
nﬂammation than control mice, mediated by p38 MAPK inhibition,
nd increased caspase activity in lung cancers [99]. The primary
eceptor for GDF15 remains to be identiﬁed. Structural similarity
ith TGF- suggests that GDF15 may  be a ligand for the TGF-
eceptor. Phosphorylation of the TGF- substrate Smad2 occurs in
esponse to GDF15 stimulation in breast cancer cells [79]; however,
irect evidence of the receptor has not yet been provided in the lit-
rature. Further, the multiple forms of endogenous versus secreted
DF15 may  have differential functions, including as a growth sup-
ressor, mediator of invasion, and anti-inﬂammatory factor, which
omplicates drug development efforts targeting GDF15. However,
ts high circulating levels in metastatic forms of various cancers
uggest that it may  be a relevant predictor of disease progression
nd possibly a novel molecular target in metastatic cancers that are
efractory to standard therapies.
.6. AT-rich interactive domain 1A (ARID1A)
The switching defective/sucrose nonfermenting (SWI/SNF)
omplex is an ATP-dependent, chromatin-remodeling, multiple-
ubunit enzyme critical for many biological processes including
ellular differentiation and proliferation [104,105]. Several sub-
nits of the complex are crucial for proliferation control and
unction as tumor suppressors in various cancer types [106]. It is
stimated that loss of SWI/SNF complex components is a critical
vent in carcinogenesis in 10–20% of solid tumors [107]. ARID1A
ncodes a human homolog of yeast SWI1, which contains a DNA-
inding motif (AT-rich interactive domain, ARID) and is an integral
ember of the SWI/SNF complex.
Mutations in ARID1A have been detected in a wide variety
f human cancers, with the highest mutation frequency (∼50%)
ccurring in carcinomas arising from endometriosis or endometrial
issue. ARID1A mutations have also been found in renal, gastric,
nd breast tumors, medulloblastoma, clear-cell ovarian carcinoma,
ndometrioid ovarian carcinoma, endometrioid endometrial can-
er and transitional cell carcinoma [108–118].
ARID1A is located on chromosome 1p and its protein product
s predominantly localized to the nucleus. ARID1A was initially
iscovered to be a p300/cAMP response element binding pro-
ein (CBP)-associated partner that participates in recruitment of
he SWI/SNF complex to speciﬁc transcription sites [119]. ARID1A
ontains an AT-rich DNA-interacting domain (ARID) and a gluco-
orticoid receptor binding domain which stimulates glucocorticoid
eceptor-dependent transcriptional activation [120].
ARID1A mutation is highly associated with loss of ARID1A
xpression. However, ARID1A protein expression is also low or
bsent in some tumors that lack mutations in ARID1A. ARID1Acer Biology 35 (2015) S55–S77 S61
is a nucleo-cytoplasmic protein whose stability depends on
its subcellular localization. Nuclear ARID1A is less stable than
cytoplasmic ARID1A because ARID1A is rapidly degraded by the
ubiquitin-proteasome system in the nucleus [121]. Another study
showed that the promoter region of ARID1A is highly methylated
in many invasive breast cancers. Promoter hypermethylation
correlates with decreased expression of ARID1A in invasive ductal
carcinomas of the breast [122]. These results demonstrate that
there are multifaceted mechanisms to regulate ARID1A expression
that include ubiquitination and promoter hypermethylation.
ARID1A suppresses cancer cell growth through several distinct
mechanisms: (1) Inhibition of cancer cell proliferation: restoration
of wild-type ARID1A expression suppressed cellular prolifera-
tion, colony formation and tumor growth in mice, whereas gene
silencing of ARID1A in non-transformed epithelial cells enhanced
cellular proliferation and tumorigenicity [110,121,123]; (2) Differ-
entiation: ARID1A knockdown disrupted differentiation of cultured
osteoblasts. The C-myc promoter is a direct target of mammalian
ARID1A containing the SWI/SNF complex during preosteoblast
differentiation. ARID1A is required for repression of C-myc dur-
ing differentiation [124]; (3) Apoptosis: shRNA-mediated ARID1A
knockdown inhibited both Fas-induced caspase-8 cleavage and
FAS-induced mitochondrial leakage and led to inhibition of Fas-
mediated cell death in Jurkat T cells. Knockdown of ARID1A in a
leukemia cell line also conferred resistance to Fas-mediated apo-
ptosis [125]; (4) Cell adhesion: The SWI/SNF complex regulates
the expression of several important cell-adhesion proteins, such
as CD44 and E-cadherin, as well as extracellular matrix proteins
including MMPs  and integrins [107]. These proteins are known to
play important roles in tumor progression and metastasis; (5) DNA
repair: SWI/SNF is recruited to double-strand DNA break sites and
is required for efﬁcient DNA repair in vivo [105]; and (6) Immune
surveillance: Major histocompatibility complex (MHC) class I and
II gene expression is regulated by SWI/SNF [126]. Loss of SWI/SNF
function may  inhibit immune surveillance and decrease detection
of tumor cells.
Finally, ARID1A mutation or loss of ARID1A expression has pro-
gnostic and predictive value in ovarian clear-cell carcinoma, gastric
cancer, breast cancer, and bladder cancer [123] and loss of ARID1A
in ovarian clear cell carcinoma correlated with worse prognosis in
patients treated with platinum-based chemotherapy [127].
3.7. Notch pathways
Over the past decade, oncologic signaling pathways (K-Ras, Wnt,
-catenin, etc.) have emerged as being critical to the development
of neoplasia. In addition to conventional pathways, primordial
embryonic pathways have recently been thought to be integral to
the initiation and maintenance of carcinogenesis. These include
the Hedgehog and Notch embryonic pathways. In the process
of carcinogenesis, aberrant regulation of these pathways leads
to neoplasia. In addition to contributing to the process of car-
cinogenesis, dysregulation of Notch signaling has been shown
to mediate chemotherapy resistance, facilitate epithelial to mes-
enchymal transition (EMT), and also maintain the cancer stem cell
population.
Structurally, Notch signaling involves a transmembrane recep-
tor and a transcription factor, which interacts with other nuclear
proteins to control gene expression, thus transmitting growth and
proliferation signals to the cell. Notch receptors are represented
by four homologs in mammals (Notch1-Notch4), and contain a
large extracellular domain and an intracellular signaling domain
(NICD). Activation of Notch occurs through ligand binding. Two
Notch ligand families, Jagged and Delta, have been described in
mammals with ﬁve ligands identiﬁed to date (Jagged 1, 2, and
Delta 1, 3, 4). After ligand binding, two successive proteolytic
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leavage steps occur. The ﬁrst step is mediated extracellularly
y ADAM/TACE (a disintegrin and metalloprotease/tumor-necrosis
actor (TNF)  converting enzyme) and occurs at the S2 cleavage
ite. The second step occurs at the S3 cleavage site and is medi-
ted intramembranously by the -secretase complex, consisting
f a catalytic subunit (presenilin 1 or 2), and accessory subunits
nicastrin, presenilin enhancer 2 [Pen-2], and anterior pharynx-
efective 1 [Aph-1]). The resulting active form of NICD translocates
o the nucleus where it binds a transcriptional repressor known
s C promoter-binding factor (CBF-1, also known as recombina-
ion signal binding protein or immunoglobulin kappa J RBPJ), or
BF-1/suppressor of Hairless/Lag1 (CSL), converting it to a trans-
riptional activator. This NICD-CBF1 complex then activates the
ranscription of several downstream Notch target genes, such as
yc, p21, and Hes (hairy/enhancer of split) family members (for
 review of the Notch signaling pathway and its role in cancer
ee [128–130]), which in turn act as transcriptional regulators of
urther downstream genes [131–134]. In the absence of NICD, the
BF-1 protein binds to speciﬁc DNA sequences in the regulatory ele-
ents of various target genes and represses transcription of these
enes by recruiting histone deacetylases and other components to
orm a co-repressor complex.
In tumor types with activating mutations of Notch, blocking
otch signaling via -secretase inhibition produces a slower grow-
ng, less transformed phenotype in human cancer cells in vivo.
nappropriate activation of Notch signaling in T-cell acute lym-
hoblastic leukemia [135,136], breast cancer [137–139], melanoma
140–142] and lung cancer [143–145] has been shown to result in
timulation of proliferation, restriction of differentiation and pre-
ention of apoptosis. Overexpression of Notch also occurs in other
ematologic malignancies, including B-cell malignancies [128]. In
ontrast, in squamous epithelial tumors such as SCC of the oral
ucosa or skin, inactivating mutations of Notch1 are more common
nd leave the Wnt  signaling pathway unopposed, so that continu-
us growth ensues. In squamous epithelium, Notch1 signals the
ell to undergo differentiation at the basal suprabasal junction. The
evelopment of benign skin tumors has been observed in patients
aking -secretase inhibitors because of Notch1 inhibition.
A variety of cancers have been characterized by aberrant Notch
ignaling, which serves an oncogenic function [146,147]. This asso-
iation was ﬁrst described in T cell acute lymphoblastic leukemia
here it was found that point mutations of the Notch receptors lead
o constitutive over-activation [147]. More recently, over the past
ecade, several studies have emerged suggesting that dysregulated
otch activity is also involved in the inception and maintenance
f other human cancers such as glioma, melanoma, breast can-
er, pancreatic cancer, medulloblastoma, and colorectal carcinomas
131,148–150].
More recently, the role of Notch as an important tumor sup-
ressor has been illustrated in the pathogenesis of pancreatic
ancer. Pancreatic cancer is a highly aggressive malignancy with
 very poor prognosis. Effective treatment options are very limited
argely due to the innate chemotherapy and radiotherapy resis-
ance that characterizes this aggressive neoplasm. Interestingly,
otch signaling has been found to be important in the pathogen-
sis of chemo-resistance and radio-resistance of pancreatic cancer
nd also in the process of pancreatic carcinogenesis from initi-
tion to cancer formation and maintenance. The study of Notch
unction in the pancreas, however, has been limited by early embry-
nic lethality of mice with Notch signaling deﬁciency, and thus
ost data exist for early pancreatic organogenesis. It has been
hown that activation of Notch 1 prevented exocrine and endocrine
ifferentiation of pancreatic progenitor cells, leaving them in an
ndifferentiated state [151,152]. Thus Notch signaling regulates
ell fate decisions in both exocrine and endocrine lineages during
rganogenesis. The role of Notch during later embryonic stages andcer Biology 35 (2015) S55–S77
in adult tissue homeostasis is also being investigated. In the adult
pancreas, Notch is normally suppressed except for in the centroaci-
nar cells [153], while Notch target genes and signaling molecules
are upregulated in invasive pancreatic cancer in addition to pancre-
atic precursor lesions from both mice and humans, suggesting that
Notch might play an important role in the process of pancreatic car-
cinogenesis. Moreover, aberrant activation of the Notch signaling
pathway has also been demonstrated in several transgenic models
of pancreatic cancer [154].
3.8. Evading apoptosis
Evasion of apoptosis is a hallmark of cancer [43]. During prolifer-
ation and/or growth, cancer cells encounter a variety of unfavorable
conditions, such as an insufﬁcient supply of growth factors, oxygen,
and other nutrients. Under these harsh circumstances, cells gen-
erally undergo regulatory programs that induce cell cycle arrest,
apoptosis, and/or other types of programmed cell death; many of
these programs are modulated by the actions of various tumor
suppressor genes, such as p53 and Rb. However, cancer cells can
circumvent these programs by activating several pathways that
promote cell survival and proliferation. Of these bypassing path-
ways, the insulin-like growth factor receptor (IGF-1R)-mediated
signaling cascade, which is regulated by ligands, receptors, and
IGF-binding proteins, plays a key role in sustained cell survival and
proliferation and the evasion of apoptosis. Accordingly, a number
of clinical trials directly targeting IGF-1R have been conducted in
various cancer types; however, these have met  with only modest
or unsustained efﬁcacy through yet to be identiﬁed mechanisms.
Recent studies have implicated IGF-1R-mediated signaling as a
main player in the control of cancer cell proliferation, growth, and
survival. The IGF-1R signaling axis is composed of ligands (IGF1 and
IGF2), receptors (IGF-1R, IGF-2R, and IR), and IGF-binding proteins
(IGFBPs) [155]. IGFs are polypeptides that are structurally similar
to insulin (approximately 50% homology to insulin) [156]. IGFs are
mainly produced in the liver upon stimulation of growth hormone
(GH) and inﬂuence autocrine, paracrine, and endocrine systems
[155]. IGF1 displays high afﬁnity for IGF-1R and the IGF-1R/insulin
receptor (IR) hybrid receptor, while having a relatively low bind-
ing capacity for IGF-2R or IR [155,157]. In contrast, IGF2 possesses
high binding afﬁnity for the IR-A isoform as well as IGF-1R, IGF-2R,
and the IGF-1R/IR hybrid receptor [155,157]. IGF-1R and IGF-2R are
glycoproteins located on the cell membrane. IGF-1R is a receptor
tyrosine kinase that exists as a tetrameric 22 complex and can
be associated with IR to form the IGF-1R/IR hybrid receptor [158].
In contrast, IGF-2R is a monomer with no tyrosine kinase activ-
ity and the binding of IGF2 to IGF-2R results in the termination
of IGFR-mediated signaling activation. Activation of IGF-2R exerts
anti-proliferative and pro-apoptotic activities [159] via a variety of
mechanisms, such as binding and subsequent internalization and
degradation of IGF-2 [158], surface activation of the latent TGF-
[160], or serving as a receptor for retinoic acid [161].
Binding of an IGF to its receptor induces autophosphorylation of
the receptor, stimulation of intrinsic tyrosine kinase activity, and
phosphorylation of cellular substrates including insulin receptor
substrate 1 (IRS-1), leading to gene activation and ultimately to
proliferation or differentiation of cells [155]. Two  distinct signal
transduction pathways for IGF-IR with major roles in transmitting
the cellular effects of IGFs have been identiﬁed: the Ras/Raf/MAPK
and the PI3K/Akt pathways [155,162]. PI3K, which is also a Ras
mediator, phosphorylates the D3 position of phosphatidylinositol
on PI4P and PI(4,5)P2 to produce PI(3,4)P2 and PI(3,4,5)P3 [163].
This mechanism is negatively regulated by the PTEN tumor
suppressor that dephosphorylates the 3′ sites of PI(3,4)P2 and
PI(3,4,5)P3 [163]. PI(3,4,5)P3 and PI(3,4)P2 recruit intracellular
proteins containing the pleckstrin homology (PH) domain to the
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ytoplasmic membrane, which is an essential event in the activa-
ion of PI3K-dependent kinases such as pyruvate dehydrogenase
inase (PDK-1) and Akt/PKB [164,165]. The serine/threonine
rotein kinase Akt is a direct target of PI3K. Three members of this
amily, Akt1/PKB,  Akt2/PKB,  and Akt3/PKB,  are activated by
rowth factors, integrins, and signals initiated by the stimulation
f GPCR [165–168]. Activated Akt promotes cell survival and blocks
poptosis by phosphorylating substrates such as Bad, caspase-9,
uman telomerase reverse transcriptase subunit, transcription
actor FKHRL1, GSK-3,  and IB kinases [164,169]. Activated
GF-1R recruits the adaptor protein Shc, which, in turn, mediates
he binding of growth factor receptor-bound protein 2 (Grb2)
ia its SH2 domain. Grb2 further recruits a guanine nucleotide
xchange factor son of sevenless (Sos), which then activates Ras
hrough converting bound GDP to GTP. Activated Ras stimulates
he sequential Raf/MEK/ERK cascade, which upregulates the phos-
horylation and activation of target transcription factors c-jun and
TS domain-containing protein (Elk-1), eventually leading to the
romotion of cell cycle progression through modulating cyclin D1,
21, and p27 expression.
High levels of IGF-1R activation have been observed in early
tage lung carcinogenesis [170] and in several sarcoma subtypes
171]. A variety of stimuli, such as platelet-derived growth factors
PDGF) and ﬁbroblast growth factor (FGF), hormones (androgen and
strogen), and various transcription factors, such as Sp1, NF-B,
nd estrogen receptor-  (ER), have been reported to stimulate
he promoter activity of the Igfr gene, resulting in increased levels
f IGF-1R expression [172–175].
The IGF system is also regulated by six IGFBP family mem-
ers that bind to IGFs in the extracellular milieu with high afﬁnity
nd speciﬁcity, thus reducing the bioavailability of IGFs [176,177].
ore than 99% of circulating IGF is bound to IGFBPs, and at
east 75% of bound IGF is carried as a trimeric complex com-
osed of IGFBP-3 and the acid labile subunit [177]. At the tissue
evel, IGFBPs interact either with extracellular matrix constituents
IGFBP-2 and IGFBP-5) or directly with cell membranes (IGFBP-
 and IGFBP-3), thereby regulating the interaction between IGFs
nd IGF-IR [178]. With the exception of IGFBP-6, which binds
o IGF-2 with two times greater afﬁnity than it does to IGF-1,
he IGFBPs bind to IGF-1 with greater afﬁnity, thereby regulating
he mitogenic and anti-apoptotic activity of IGFs [176,178,179].
n addition to their modulatory role in IGF action, IGFBP-3 and
GFBP-5 have IGF-independent antiproliferative and pro-apoptotic
ffects in a variety of cancers [180–182]. Direct functional inter-
ctions between IGFBP-3 and the retinoid X receptor (RXR) have
een shown to regulate transcriptional signaling and apoptosis
183]. IGF-independent antiangiogenic and antiproliferative effects
f IGFBP-3 in human lung and head and neck cancer cells are also
ossible [184,185]. IGFBP-3 action is modulated by posttransla-
ional modiﬁcations, including proteolysis, phosphorylation, and
lycosylation [181]. The cleavage of IGFBPs by a variety of protease
amilies including kallikrein-like serine proteases, cathepsins, and
MPs reduces the afﬁnity for IGFs [179]. However, the role of these
osttranslational modiﬁcation and proteolytic processing events in
he regulation of IGFBP stability and function appears to be virtually
nexplored.
A number of tumor suppressor genes, such as p53, PTEN, breast
ancer gene 1 (BRCA1), Von Hippel–Lindau (VHL), Wilms  tumor 1
WT1), and Klotho, are negative regulators of IGF-1R transcription
nd/or activation [186–188]. Studies have revealed, however, that
hese tumor suppressors are frequently mutated in several types
f human cancers [189]. An inherited germline mutation in the Rb
ene is the ﬁrst identiﬁed tumor suppressor gene implicated in sev-
ral types of neoplasia, including familial retinoblastoma, small-cell
ung cancer, and osteosarcoma [7,189]. Therefore, loss or muta-
ion of these tumor suppressor genes may  contribute to evadingcer Biology 35 (2015) S55–S77 S63
growth-inhibitory and/or cell death signals in tumors that succeed
in maintaining sustained proliferation and progressing to states of
high-grade malignancy.
IGFs regulate cell growth, differentiation, and apoptosis [190].
Imbalance of these diverse processes favors uncontrolled cell pro-
liferation, leading to malignant transformation. In addition, IGFR
signaling facilitates angiogenesis and cancer cell metastasis by
inducing angiogenic factors and proteases, including hypoxia-
inducible factor-1 (HIF-1)  expression, which promotes the
expression of vascular endothelial growth factor (VEGF) [191],
interleukin-8 (IL-8) [192,193], MMPs  [190,194] and uPA [190]. In
addition, Akt, a downstream protein of IGF-1R-mediated signaling,
enhances MDM2-mediated ubiquitination and proteosomal degra-
dation of p53 [195]. A recent report indicates that activated IGF-1R
increases the expression of oncogenic initiation of differentiation
2 (Id2) via upregulation of PI3K-Akt activity [196]. These ﬁndings
indicate a possible oncogenic role of IGFR. IGFR signaling is also
involved in intrinsic or acquired resistance to various conventional
anticancer chemotherapies, radiation therapy, and recently devel-
oped molecularly targeted anticancer drugs, including tyrosine
kinase inhibitors (TKIs) blocking EGFR, HER2, or BRAF [197–200].
Increased IGF2 expression is also found in paclitaxel-resistant ovar-
ian cancer cells [201]. Taken together, these ﬁndings implicate
IGF-1R as a promising target for anticancer therapy.
3.9. Tumor suppressor gene – context dependent functions of
Krüppel-like factor 5 (KLF5)
Deletion of the long arm of human chromosome 13 (13q),
especially the region involving 13q21, is the second most fre-
quent chromosomal deletion revealed by comparative genomic
hybridization among a large number of different types of human
tumors [202]. After analyzing the genomes from hundreds of
human prostate and breast cancers, the deletion at 13q21 was
mapped to 142-kilobases of the smallest region of overlap, in
which the KLF5 gene was the only complete gene and was
thus identiﬁed as a reasonable candidate for the 13q21 tumor
suppressor gene [203,204]. The majority of KLF5 deletions in can-
cers are hemizygous, i.e.,  one of the two KLF5 gene copies is
deleted. It has been shown that KLF5 needs both copies to yield
sufﬁcient product, and deletion of one copy causes functional
insufﬁciency–haploinsufﬁciency [205] – so hemizygous deletion
impairs KLF5 function during tumorigenesis.
In addition to chromosomal deletion, excess degradation at
the protein level has been identiﬁed as another common mech-
anism of KLF5 inactivation during tumorigenesis. KLF5 protein is
ubiquitinated and degraded by the ubiquitin proteasome pathway
[206], and the WW domain containing E3 ubiquitin protein ligase 1
(WWP1) mediates the ubiquitination of KLF5 [207]. Interestingly,
the WWP1  gene is located at a chromosomal region that under-
goes frequent copy number gains in human cancers, and WWP1
is indeed often ampliﬁed and overexpressed in human cancers,
causing excess degradation of KLF5 protein [208,209]. There-
fore, KLF5 is inactivated by two  mechanisms: genomic deletion
and excess protein degradation, indicating that KLF5 undergoes
frequent functional inactivation during tumorigenesis and thus
should be considered a tumor suppressor gene. Expression of KLF5
mRNA is frequently reduced or absent in prostate and breast can-
cer cell lines [203,204]. In gastric cancer, loss of KLF5 expression
occurs more frequently in late stage tumors, in larger tumors, and
in tumors with lymph node metastasis [210].
Consistent with a tumor suppressor function, KLF5 has also been
found to inhibit cell proliferation and suppress tumorigenesis. Inhi-
bition of cell proliferation has been shown for cancer cell lines from
the esophagus, prostate, breast, and epidermis [204,211,212], as
well as for non-tumorigenic epithelial cells [213]. In prostate cancer
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ells, KLF5 has been shown to suppress tumorigenesis in xenograft
odels, and the suppression was suggested to require ER and its
ssociation with KLF5 and the transcription coactivator CBP on the
romoter of FOXO1 and subsequent activation of FOXO1, which
nduces anoikis in prostate cancer cells thereby suppressing tumor
rowth.
In contrast, KLF5 can also be tumor promoting, and the reverse
f its function can be determined by posttranslational modi-
cation, speciﬁcally the acetylation of lysine 369 (K369). The
ncogenic activity of KLF5 was originally suggested by in vitro
tudies in which KLF5 was shown to be upregulated in onco-
enic H-Ras-transformed NIH3T3 cells [214], and overexpression
f KLF5 promoted cell proliferation and induced the transfor-
ation of ﬁbroblasts [215] and IEC-6 intestinal epithelial cells
216]. In the TSU-Pr1 bladder cancer cell line, expression of KLF5
romotes cell proliferation and tumorigenesis by inducing the
xpression of many genes [217]. The tumor promoting function
f KLF5 has also been shown in breast cancer cells [218]. Knock-
own of KLF5 inhibits multicellular tumor spheroid formation
n vitro [219]. In transgenic mice, overexpression of KLF5 promotes
he proliferation of basal epithelial cells, but does not produce
umors [220]. In the epidermis, expression of KLF5 is at relatively
igher levels in keratinocytes, and overexpression of KLF5 in the
asal layer of the epidermis affects epidermal development and
isrupts epithelial–mesenchymal interactions necessary for skin
dnexae formation [221]. KLF5 promotes cell proliferation through
ccelerating the G1/S and G2/M cell cycle progression and other
echanisms [216,217]. Regulation of cell cycle regulators by KLF5
ncludes the induction of cyclin D1, cyclin B1, Cdc2, Myc, EGFR etc.
nd the inhibition of p27, p15 etc. [217,222,223].
How KLF5 can be both pro- and anti-tumorigenic is unknown
t present. However, a mechanism has been suggested for the
eversal of KLF5 functions in gene regulation and cell prolifera-
ion control. Using a cultured epidermis epithelial cell line – HaCaT,
 model widely used to dissect the TGF- signaling pathway –
t was demonstrated that KLF5 is a cofactor for TGF-, which
nhibits cell proliferation and suppresses early stage tumorigenesis.
s reported in several publications [213,224,225], without TGF-,
LF5 forms a transcriptional complex with other transcription fac-
ors to repress cell cycle inhibitors such as the p15 CDK inhibitor
nd induce cell cycle promoting genes such as Myc  to promote
ell proliferation. When TGF- is present, KLF5 forms a different
ranscriptional complex with a reversed function: inducing p15
ranscription but repressing Myc  transcription, which results in the
nhibition of cell proliferation. The molecular basis for the reversal
f KLF5 function in gene regulation and cell proliferation control is
GF--induced acetylation of KLF5, because interruption of KLF5
cetylation by mutating its acetylation residue prevents the func-
ional reversal of KLF5 [213,224,225]. In mouse prostate tissues,
nacetylated KLF5 (unAc-KLF5) is expressed in basal or undiffer-
ntiated cells, whereas acetylated KLF5 (Ac-KLF5) is expressed
rimarily in luminal and/or differentiated cells [226], which is
onsistent with a pro-proliferative function of unAc-KLF5 and anti-
roliferative function of acetylated KLF5 in cultured cells.
Based on the available information described above, Ac-KLF5
nd unAc-KLF5 have opposing functions in gene regulation and
ell proliferation, which could correspond to its opposing functions
uring tumorigenesis: Ac-KLF5 is responsible for the tumor sup-
ressor function of KLF5 whereas unAc-KLF5 is responsible for the
ncogenic function of KLF5 during tumorigenesis. It is well estab-
ished that the function of TGF- switches from that of a tumor
uppressor in the early stages of tumorigenesis to a tumor promoter
n late stage tumor progression [227]. How TGF- switches function
s an intriguing question, and some studies have been published to
ddress this question. It is possible that KLF5 is essential for TGF-
’s tumor suppressor function, and interruption of TGF--inducedcer Biology 35 (2015) S55–S77
KLF5 acetylation is a key to the reversal of TGF- function during
tumorigenesis. These predictions are currently under investigation.
4. Safety considerations and multi-targeted approach to
chemoprevention and therapy with natural compounds
The Latin adage primum non nocere (ﬁrst, do no harm) that
characterizes medical practice over centuries applies perfectly to
the prevention/therapy of cancer or any other disease. In particu-
lar, recipients of chemopreventive drugs are not cancer patients,
but are healthy people who  are at high risk for developing cancer
such as smokers or those with hepatitis B. Since these essentially
healthy people will receive the chemopreventive treatment for a
long period of time, the toxicity of the agents severely impacts
patient accrual and retention for prevention trials. Toxicity is also
a major concern for chemotherapeutic drugs. An ideal compound
for both chemoprevention and therapy should be nontoxic, orally
active, economical, and easily available. Unlike synthetic com-
pounds, natural compounds have been found safe in long term
human consumption in the diet and many of them exhibit poten-
tial chemopreventive and anti-tumor effects in preclinical studies
[228,229]. Moreover, the safety and tolerability of many of these
natural compounds in pharmacological doses has been established
through phase I safety trials.
As described earlier, multiple genetic and epigenetic changes
accumulate throughout the carcinogenesis process. While tar-
geting one or two of these pathways using speciﬁc agents may
not be effective or durable, most natural compounds hit multiple
targets [228,229]. Therefore, long-term use of natural com-
pounds can be an effective and rational strategy for populations
at high risk of developing cancers. Clinicians are also paying
increasing attention to diet-derived chemopreventive agents as
a result of patient preference. Since the recognition of chemo-
prevention, the National Cancer Institute (NCI) has investigated
or sponsored more than 1000 different potential agents for
chemoprevention, of which only about 40 promising agents have
been moved to clinical trials including several natural agents
http://prevention.cancer.gov/programs-resources/resources/agents.
Most preclinical studies using natural compounds were conducted
using fully transformed cancer cell lines due to the lack of pre-
malignant cell lines, suggesting that these compounds can also be
used for treatment of cancers.
5. Prophylactic and therapeutic potential of targeting
anti-growth signaling with natural compounds
Carcinogenesis is a lengthy process, sometimes taking decades
for normal cells to transform into invasive cancers. Because of
the lengthy transformation process, with several precancerous
pathologic stages preceding the change to invasive cancer, there
are enormous opportunities to intervene, with the aim to reverse
or slow down the transformation process [1,230]. Such inter-
vention is known as cancer prevention and the use of natural or
synthetic agents at pharmacological doses for cancer prevention
is called chemoprevention. Chemoprevention is a cost-effective
alternative to chemotherapy and its successful implementation
may  save millions of lives worldwide. An outstanding review
article written by Haddad and Shin [1] elegantly describes the
general carcinogenesis process with associated genetic and
pathologic changes and the article by William et al. [230] distin-
guishes between chemoprevention and chemotherapy. While the
purpose of chemoprevention is to eliminate or slow down the
progression of intraepithelial neoplastic or precancerous lesions
to invasive cancer, the purpose of chemotherapy is to stop or
slow down the growth of fully transformed cells or to eliminate
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hem through activating cell death pathways. Since anti-growth
ignaling via tumor suppressors challenges tumorigenesis by
nhibiting the growth of damaged cells, repairing damage, or
liminating damaged cells through apoptosis or other forms of
ell death mechanisms, the reactivation of these pathways using
hemical compounds or genetic approaches has high prophylactic
nd therapeutic potential. Activation (if normal and wild-type)
r reactivation (if inactivated via reversible process) of tumor
uppressor genes and/or pathways might serve as crucial events
or effective chemoprevention and therapy, as discussed later.
.1. The Rb pathway
The RB-E2F pathway is one of the most important tumor sup-
ressor pathways frequently inactivated or lost in human cancers.
s described in section 3.1, Rb and p16ink4a are critical regu-
ators of proliferation. This makes the cyclinD1/CDK4/6 complex
n interesting target for chemopreventive and chemotherapeu-
ic drug development. Green tea-derived galloyl polyphenol and
pigallocatechin gallate (EGCG) were shown to decrease the phos-
horylation of Rb, and as a result, cells were arrested in G1 phase
231]. Several studies also revealed that green tea polyphenols
trongly inhibited CDKs or cyclin D1 to exert their chemopreventive
anti-proliferation and cell cycle arrest) effects, which might occur
hrough decreasing the phosphorylation of Rb proteins [232,233].
estoration of Rb expression by curcumin in cervical cancer cells
234] and inhibition of the Rb pathway by enhancing CDKN2A/p16
nd suppressing phosphorylated Rb in glioblastoma [235] were
eported and associated with the chemopreventive potential of
urcumin. It has been reported that 1,25-dihydroxivitamin D, the
ost biologically active metabolite of the micronutrient vitamin D,
xerts potent effects on the Rb signaling axis. For example, it sup-
resses PDGF-induced myocyte proliferation in vitro by inhibiting
b and checkpoint kinase 1 (Chk1) phosphorylation [236]. In some
umor cells, the natural compound honokiol, derived from trees of
he Magnolia genus, activated the production of reactive oxygen,
eading to increased phosphorylation of Rb [237].
.2. The p53 pathway
According to TCGA data available so far, p53 is the most fre-
uently mutated tumor suppressor protein. However, for many
umors p53 is wild-type but inactivated via secondary mechanisms
ather than by loss or mutation. Drugs are available and currently
nder clinical development which inhibit or remove the negative
egulator MDM2,  thus restoring p53 function leading to growth
nhibition and induction of apoptosis. Some of these drugs are DS-
032b, RO5503781, RO5045337, SAR405838 etc. As discussed in
ection 3.2, viral oncogene-driven tumors also retain wild-type 53
nd can be treated with DNA-damaging drugs such as cisplatin,
oxorubicin, taxols etc. or radiation therapy. Finally, drugs are
lso under development that reactivate mutant p53, for example,
RIMA-1 and APR-246.
Many natural agents exert their chemopreventive/anti-tumor
ffects through the induction of cell cycle arrest or apoptosis by
ctivating the p53 pathway. Groups of investigators at Emory
niversity and other institutions have extensively studied these
olecular pathways and natural compounds. The green tea com-
onent EGCG was shown to activate p53 and its target p21 and
ax in prostate cancer cells with wild-type p53 [238], and Bax
n breast carcinoma cells [239]. The vegetable-derived compound
uteolin was shown to induce cell cycle arrest and apoptotic effects
s well as increased chemosensitization effects associated with
he activation of p53 and its targets p21, Bax, and PUMA [240].
uteolin and a combination of luteolin and EGCG also induced
itochondrial translocation of p53 in lung cancer cell lines [241].cer Biology 35 (2015) S55–S77 S65
Another extensively investigated dietary chemopreventive agent,
curcumin, was  reported to activate p53 and its transcriptional
target Bax in breast and bladder cancers [242,243] and induce
mitochondrial translocation in prostate cancer [244]. Resveratrol,
a component of red wine and grape skin, also activated p53 and its
target genes p21, p27, Bax, PUMA, MDM2,  and cyclin G [245,246].
Genistein, an isoﬂavone and dietary chemopreventive agent from
soy also activated p53 and induced G2/M arrest and apoptosis in
human malignant glioma cell lines through p21 induction [247].
Activation of p53 was also reported by glycyrrhizic acid in the colon
of Wister rats [248], by oleanolic acid in HepG2 transplanted Balb/C
mice [249], by amarogentin, a secoiridoid glycoside active compo-
nent of the medicinal plant Swertia chirata,  in a carbon tetrachloride
(CCl4)/N-nitrosodiethylamine (NDEA)-induced liver carcinogene-
sis mouse model [250], by melatonin in cell culture models of
MCF-7 and HCT116 [251] and by Kaempferol in A2780/CP70,
A2780/wt, and OVCAR-3 ovarian cancer cell lines [252]. An emerg-
ing role for p73 activation by natural chemopreventive agents has
also been reported. EGCG induced apoptosis by activating p73-
dependent expression of a subset of p53 target genes including
p21, reprimo, cyclin G1,  PERP, MDM2,  WIG1, and P53-induced gene
11 (PIG11) in mouse embryonic ﬁbroblasts [253]. Upregulation of p73
was reported in response to EGCG in multiple myeloma cells [254].
Polyphenol-rich Aronia melanocarpa juice induces cell cycle arrest
and apoptosis by redox sensitive activation of p73 [255].
Many natural compounds also suppress carcinogenesis by acti-
vating upstream or downstream components of the p53 pathway.
Curcumin downregulates expression of MDM2  at the transcrip-
tional level in a p53-independent manner, which ultimately
upregulates p21 and induces apoptosis in a prostate cancer cell line
[256]. Using yeast-based assays, gene reporter assay and computa-
tional docking, Leao et al. [257] reported that natural compounds
-mangostin and gambogic acid inhibited p53-MDM2 interac-
tion by binding with MDM2.  Disruption of p53-MDM2 interaction
is critical for p53 stabilization. Such interaction is inhibited by
other natural compounds [258,259]. Herman-Antosiewicz et al.
[260] reported activation of ATR/checkpoint kinase 1-dependent
prometaphase checkpoint in cancer cells by the processed garlic
constituent diallyl trisulﬁde. Vitamin D exerts its chemopreventive
effects in a chemically induced carcinogenesis mouse model by
promoting expression of the DNA repair genes RAD50 and ataxia-
telangiectasia mutated (ATM) and maintaining a positive feedback
loop between ATM and vitamin D receptor [261]. The activation
of p53 by luteolin also occurs through activation of ATM [241].
The chemopreventive agent selenium also activates DNA damage
response by activating ATM [262]. Honokiol is active in cells with
both wild type and mutant p53. Studies have shown that tumors
with mutant p53 are particularly susceptible to honokiol, especially
in the presence of oncogenic Ras. Honokiol decreases the level of
Ras in the active GTP conﬁguration [263].
5.3. Epigenetic silencing
Many tumor suppressor proteins are also inactivated via epi-
genetic silencing. Covalent modiﬁcations of histone proteins and
DNA hypermethylation of promoters or CpG islands are impor-
tant epigenetic silencing mechanisms through which tumor cells
evade tumor suppressors, and epigenetic intervention is even
possible at the precancerous stage [264]. Unlike genetic inactiva-
tion, epigenetic inactivation is reversible. DNA methyl transferases
(DNMT) are key enzymes regulating DNA methylation and inhi-
bition of such enzymes will reactivate tumor suppressors. Many
natural polyphenols act as demethylating agents and reactivate
tumor suppressors. In silico docking studies have revealed that
curcumin may  compete with the cofactor S-adenosyl methionine
(SAM) for binding to the catalytic pocket of DNMT and induce
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lobal DNA hypomethylation in leukemia cells [265]. Curcumin
lso decreased p300, histone deacetylase (HDAC) 1 and 3 and
300 histone acetyltransferase (HAT) activity to modify chro-
atin acetylation [265–267]. Curcumin inhibited the expression
f DNMT1 in vitro and in a xenograft model which subsequently
eactivated the expression of p15 (INK4B) tumor suppressor by
romoter demethylation and induced cell cycle arrest and apo-
tosis [268]. In breast cancer cells, curcumin also reactivated the
umor suppressor RASSF1 through promoter demethylation by
nactivating DNMT1 [269]. Human, animal and cell culture studies
lso revealed that green tea polyphenols are strong demethylat-
ng agents and reactivate tumor suppressor genes. Nandakumar
t al. [270] reported that EGCG reactivated tumor suppressors p21
nd p16INK4a by reducing DNA methylation and increasing his-
one acetylation. In an azoxymethane-induced APC(Min/+) mouse
odel of intestinal carcinogenesis, RXR- is selectively downregu-
ated through CpG hypermethylation, and administration of green
ea as the sole source of beverage signiﬁcantly increased the protein
nd mRNA levels of RXR- as well as decreased CpG methylation
271]. In a cell culture model, EGCG was found to reverse the hyper-
ethylation of p16(INK4a), retinoic acid receptor beta (RAR),
(6)-methylguanine methyltransferase (MGMT), and human mutL
omologue 1 (hMLH1) genes, leading to a subsequent increase in
heir mRNA and protein expression levels [272]. This demethy-
ating activity of EGCG is associated with inhibition of DNMT1
hrough hydrogen bonding. Resveratrol and genistein also inhibited
NA methylation in cell culture and human intervention studies.
cetylation of STAT3 is elevated in tumors and inhibition of STAT3
y genetic mutation or by resveratrol treatment inhibited tumor
rowth by reactivating several tumor suppressor genes including
R˛, CDKN2A, deleted in lung and esophageal cancer 1 (DLEC1), and
TAT1 [273]. In a human intervention study in women with high risk
or breast cancer,  administration of trans-resveratrol was associated
ith decreased methylation of tumor suppressor RASSF1a [274].
.4. The PTEN pathway
Loss of PTEN activates the PI3K-AKT pathway, which is cur-
ently an attractive target for drug development. So far, no PI3K
nhibitor has obtained FDA approval, but several agents are in
linical trials, including BKM120, BYL719, RP6530, PF04691502,
F-05212384, MK2206 and others. Many natural compounds are
lso reported to inactivate the PI3K-AKT pathway either by acti-
ating PTEN or inactivating oncogenes that drive AKT activation.
or example, the chemopreventive agent indole-3-carbinol (I3C), a
atural indolecarbinol compound derived from the breakdown of
lucobrassicin produced in cruciferous vegetables such as broccoli
nd Brussels sprouts, induced G1-phase cell-cycle arrest and apo-
tosis and inhibited the in vivo tumor growth rate by stabilization
f PTEN in human melanoma cells that express wild-type PTEN, but
ot in cells with mutant or null PTEN genotypes [275]. Curcumin
reatment signiﬁcantly resulted in the inhibition of cell prolifera-
ion and an increase in the apoptosis rate through the upregulation
f PTEN associated with a decrease in DNA methylation level via
ownregulation of DNMT3b in vivo and in vitro [276]. Many other
tudies also support that the PTEN-AKT pathway is a major in vitro
nd in vivo target of curcumin [277]. Reactivation of PTEN by resver-
trol has also been reported [278].
.5. The Hippo pathway
Porphyrin molecules have been shown to inhibit YAP/TEAD
ctivity, suggesting that the negatively regulated targets of the
ippo pathway can be reduced [61]. Critically, the tumorous over-
rowth that occurs when NF2 is conditionally disrupted in mice is
nhibited with these molecules in vivo. The ligands glucagon andcer Biology 35 (2015) S55–S77
epinephrine enhance LATS1/2 activity, thus enhancing YAP inhibi-
tion through GPCR signaling [62]. This indicates it may be possible
to enhance or potentiate the growth suppressive effects of the path-
way using GPCR agonists, and that this branch of the GPCR family
may  be an important potential therapeutic target.
5.6. GDF15
Because of its potential growth suppressive function, GDF15
may  inhibit cancer progression [83]. It is possible that endoge-
nous GDF15 mediates the bulk of the growth suppressive activities,
and the secreted mature dimer may  mediate disease progression.
There are multiple cellular forms of GDF15, including pro-GDF15
monomer, pro-GDF15 dimer, pro-peptide N-terminal fragment,
and mature dimer [65]. The N-terminal pro-peptide fragment and
the mature dimer are rapidly secreted [65,83]. The mature dimer is
believed to be the main bioactive form. However, it remains unclear
whether the other forms are biologically active, or whether relative
expression levels or ratios of the different forms affect the biologi-
cal behavior of the cell. Further investigation is needed to establish
the relative expression levels of each form in various cancer types
and the functional differences between each form. These studies
will be important for determining the overall suitability of GDF15
as a target in metastatic cancer.
The anti-cancer ﬂavonoids resveratrol and genistein were
shown to induce GDF15 expression in a p53-dependent manner
in various types of cancer cell lines, including colorectal, osteosar-
coma, and lung cancer cell lines [279,280]. Another anti-cancer
ﬂavonoid, apigenin, was proposed to induce GDF15 expression in
a p53-independent manner [281]. Induction of GDF15 in response
to anti-cancer drugs and subsequent reductions in MCF-7 breast
tumor xenograft volumes correlated with increased ERK1/2 phos-
phorylation [100]. Thus, MEK  signaling and p53 function may be
critical mediators of GDF15 expression and growth suppressive
function.
GDF15 has been proposed to be a predictor of all-cause mor-
tality [282–284]. Therefore, serum GDF15 levels may indicate the
presence of a number of different life-threatening disorders or gen-
erally poor health. GDF15 serum evaluation may  have a role in
general health assessment and blood panels. Routine assessment
of GDF15 serum levels may  also serve as a minimally invasive way
of predicting cancer presence or progression.
5.7. ARID1A
No drugs are currently available that directly target ARID1A.
However, ARID1A could interact with several pathways to exert its
tumor suppression activities and drug development is underway
to target such pathways. These include: (1) PI3K-AKT pathway:
ARID1A mutations were also signiﬁcantly associated with the
presence of PIK3CA-activating mutations in tumors, suggesting
that ARID1A inactivation may  synergize with PIK3CA activation
to facilitate cellular transformation [110]. Another study showed
that PIK3CA mutations and loss of ARID1A protein expression
are early events in the development of cystic ovarian clear cell
adenocarcinoma [285]. Liang et al. demonstrated that ARID1A
siRNA knockdown in endometrial cancer cell lines increased AKT
phosphorylation, implicating ARID1A as a novel regulator of PI3K
pathway activity [286]. The results indicate that ARID1A and
PIK3CA mutations coexist and potentially cooperate in oncoge-
nesis. (2) P21 pathway: p21 is a potent CDK inhibitor (CKI). The
p21 (CIP1/WAF1) protein binds to and inhibits the activity of
cyclin-CDK2 or -CDK1 complexes, and thus functions as a regulator
of cell cycle progression at G1 [287]. p21 is downregulated by
ARID1A shRNAs in endometrial cancer cell lines [121]. These
ﬁndings suggest that ARID1A inhibits cancer cell progression
in Cancer Biology 35 (2015) S55–S77 S67
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y modulating p21 expression. Since loss of ARID1A upregulates
KT phosphorylation, compounds inhibiting AKT phosphorylation,
uch as resveratrol could be used for tumors harboring ARID1A loss.
.8. Notch pathway
Notch inhibition appears to be an attractive target for com-
ounds that might result in chemoprevention and treatment of
everal solid tumors that have aberrant Notch activation, such as
ancreatic cancer, ALL, and brain tumors. Several Notch inhibitors
ave been evaluated. Since the formation of the NICD follow-
ng Notch receptor cleavage by -secretase is a critical event in
otch signaling, -secretase inhibitors (GSI) are actively being
nvestigated as Notch pathway inhibitors. In addition to preclin-
cal studies in mice, several human clinical trials targeting different
ypes of malignancies are currently being conducted. Notch path-
ays are also targets of many natural compounds. In colon cancer
nd melanoma cells, honokiol downregulated levels of activated
otch-1, its ligand Jagged-1, and the downstream target gene Hes-1
288,289] and can be used to target Notch pathways for thera-
eutic and preventive purposes. Withaferin A is another natural
ompound that potentially targets the Notch pathway and inhibits
arcinogenesis [290].
.9. Evading apoptosis
IGF-1R signaling is a typical prosurvival pathway and is closely
ssociated with hallmarks of cancer, such as sustained activation
f growth-promoting signaling and evasion of tumor suppressor-
ediated cell death. Accordingly, a number of IGF-1R-targeted
gents, mainly anti-IGF-1R monoclonal antibodies (mAbs) and
mall molecule TKIs, have been evaluated in a variety of preclinical
nd clinical trials [291,292]. Indeed, pharmacologic interventions
hat lead to disruption of the IGF-1R pathway have shown promis-
ng activities in inhibiting tumor development and progression
s well as sensitizing anticancer therapies in preclinical models
293–295]. In addition, results from phase I or II clinical evaluations
f IGF-1R-targeted agents, especially anti-IGF-1R mAbs, demon-
trate signiﬁcant clinical response [296]. However, the therapeutic
eneﬁts shown in a subset of patients enrolled in phase II or III
linical trials were unsustained and most of the patients seemed
o acquire resistance to the IGF-1R-targeted therapies [296–298].
urthermore, recent phase III trials of an IGF-1R mAb, ﬁgitumumab,
ere terminated due to an increase in serious adverse events and
xcess mortality in the experimental arm [296]. However, clinical
rials in a number of cancer types are still in progress and the inter-
retation of previous and current clinical trials remains unclear
291].
Two major categories of drug resistance, de novo and acquired
esistance, have been suggested to attenuate the antitumor effects
f IGF-1R-targeted agents. Activation of alternative receptor- or
on-receptor tyrosine kinases or downstream molecules through
arious mechanisms have been proposed to bypass IGF-1R
ignaling, accounting for de novo resistance [299]. Increased expres-
ion and/or activation of IR, EGFR, HER2, and VEGF receptor (VEGFR)
ave been observed in various human cancers and suggested
s potential means to bypass the need for the IGF-1R pathway
300–302]. Recent preclinical studies using anti-IGF-1R antibod-
es suggest that Akt/mTOR is activated through yet to be identiﬁed
echanisms, and likely plays a vital role in the primary resistance to
n anti-IGF-1R mAb  cixutumumab [303]. Overexpression of IGFBPs,
ctivation of heat shock protein 90 (Hsp90), and the EMT  pheno-
ype have been also implicated in the resistance to IGF-1R targeted
herapies [299].
Given the myriad routes by which cancer cells resist IGF-1R-
argeted agents, the clinical utility of IGF-1R-targeted anticancer Ta
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Table  2
Cross-validation of potential therapeutic agents targeting anti-growth signaling with other hallmarks of cancer.
Phytochemical approaches
for evasion of anti-growth
signaling
EGCG Luteolin Curcumin Genistein Resveratrol Curcumin Withaferin A Deguelin
Other cancer hallmarks
Genomic instability + [308] + [309] + [310,311] + [312,475,476] + [313] + [310,311,393] 0 0
Sustained proliferative
signaling
+ [394,395] + [396,397] + [398] +/− [399,400] +/− [399,400] + [398] + [481] + [401]
Tumor promoting
inﬂammation
+ [402–404] + [405,406] + [407–409] +/− [410,411,477,478] + [412,413] + [407–409] + [414] + [415–417]
Resistance to apoptosis + [418] + [419] + [420] + [421] + [422] + [423] + [424] + [425]
Replicative immortality + [426–428] 0 0 [429,430] + [431–433] + [434,435] + [429,430] 0 0
Dysregulated metabolism + [472–474] + [241,436,437] + [235,438,439] +/− [479] 0 0 + [440] 0
Immune system evasion + [441] 0 + [442] +/− [480] 0 + [442] + [482] 0
Angiogenesis + [443] + [444] + [445] + [446] + [447] + [445] + [448,449] + [450]
Invasion and metastasis + [451,452] + [453] + [454] + [455,456] + [457,458] + [459] + [448,460] + [461]
Interactions in the tumor + [462,463] + [464,465] + [466–468] + [469] + [470] + [466–468] + [483] + [471]
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o
signaling” is a critical component of the hallmarks of cancer, othermicroenvironment
otes: “+” indicates complimentary; “−” contrary; “+/−” controversial and “0” no kn
herapies should be evaluated after the completion of extensive
tudies on the mechanisms underlying primary and acquired resis-
ance to IGF-1R targeted agents, the discovery of biomarkers to
redict the effectiveness of IGF-1R targeted therapies, and the
evelopment of effective combinational therapeutic regimens.
.10. KLF5
KLF5 appears to be a unique tumor suppressor in the sense that
ts function is context-dependent. Its tumor suppressor function
ould be dependent upon its acetylation, which can be induced by
GF- and possibly other signaling pathways. Once experimentally
onﬁrmed, how TGF- and KLF5 become oncogenic will be better
nderstood, and some unique targets could be identiﬁed for their
otential use in the detection and treatment of malignant cancer.
. Cross validation of prioritized targets and approaches
ith other hallmarks of cancer
Given the heterogeneity that is present in most cancers, it is our
ssumption that the complete arrest of the various subpopulations
f immortalized cells in any given cancer will require simultaneous
ctions on mechanisms that are important for several aspects of
ancer biology. We  therefore believe that it is important to be able
o anticipate synergies that might be achieved by acting on spe-
iﬁc targets and with speciﬁc approaches (i.e., when contemplating
n approach aimed at a broad spectrum of targets). Accordingly,
n this review, the prioritized target sites and the approaches that
ave been identiﬁed (as potential methods to reach those targets)
ere all cross-validated by undertaking a background literature
esearch. A team of researchers consisting of specialists in each
ancer hallmark area speciﬁcally sought to determine the rele-
ance of these targets and the nominated approaches across a
umber of important areas of cancer biology. In this regard, tar-
ets and approaches that were not only relevant for this area of
tudy, but also relevant for other aspects of cancer biology (i.e., anti-
arcinogenic) were noted as having “complementary” effects with
ymbol “+” in Tables 1 and 2, while those that were found to have
ro-carcinogenic actions were noted as having “contrary” effects
ith symbol “-”. In instances where reports on relevant actions in
ther aspects of cancer biology were mixed (i.e.,  reports showing
oth pro-carcinogenic and anti-carcinogenic potential), the term
controversial” was used with symbol “+/−”. Finally, in instances
here no literature support was found to document the relevance
f a target site or approach in a particular aspect of cancer biology,relationship.
we documented this as “no known relationship” with a symbol “0”.
These validation results are shown in Tables 1 and 2.
7. Conclusions and future directions
Anti-growth signaling, mainly mediated by tumor suppressor
proteins, and immune surveillance are the two  major hurdles that
must be overcome for cancer cells to acquire limitless prolifera-
tion. Since tumor suppressors function to eliminate damaged cells
or cancer cells, their activation is expected for successful cancer
therapy. Most cancer drugs currently in use, including recently
developed targeted drugs [304], activate anti-growth signaling to
prevent cell proliferation. However, the high cost of treatment and
the development of resistance to these agents are major challenges
for physicians and patients. As discussed, cancer is a multi-factorial
and heterogeneous process that involves the accumulation of mul-
tiple genetic and epigenetic changes. Resistance arises mainly due
to the development of alternative pathways for cell survival and
thus multi-targeted approaches with effects on multiple hallmarks
of cancer are critical. On the other hand, cost is mostly associ-
ated with intellectual issues, investment in development and proﬁt
of manufacturing companies. Considering these factors, natural
dietary compounds are highly attractive since they are readily
available and most are multi-targeted, affecting multiple hallmarks
of cancer. Therefore, future directions should explore the devel-
opment of natural compounds, not only for prevention but also
for therapy. Potency and bioavailability of natural compounds are
the main barriers to their clinical application, therefore special
attention should be given to combinatorial approaches of natu-
ral compounds with other natural or synthetic compounds either
to achieve synergistic effects or to increase bioavailability. Sev-
eral such combinations have shown high potential [241,305]. In
parallel, the development of potent analogs of natural compounds
and their improved delivery by novel technologies such as nano-
technology are important other directions to be considered in the
future. Importantly, proof-of-principle studies demonstrate that
the delivery of natural compounds as nanoparticles can signif-
icantly improve their efﬁcacy [306,307]. Approaches to activate
anti-growth signaling with synthetic and/or natural compounds
promise to open new chapters for cancer prevention and therapy
in the near future. Finally, although the “evasion of anti-growthhallmarks are similarly critical and a more integrative approach is
necessary to simultaneously target not only anti-growth signaling
but also other properties of cancer to combat this deadly
disease.
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